­Nevro Names D. Keith Grossman Chairman of the Board; Michael DeMane as Lead Director

­Nevro Names D. Keith Grossman Chairman of the Board; Michael DeMane as Lead Director

REDWOOD CITY, Calif., May 20, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that its Board of Directors has elected D. Keith Grossman, the Company's President and CEO, to additionally serve as Chairman of the Board.  Mr. Grossman assumes the Chairmanship effective today, following the Company's Annual Meeting of Stockholders.  Michael DeMane, who served as Chairman of the Board since January of 2017, will serve as Lead Director. 

About Nevro Corp. 
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
ir@nevro.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-names-d-keith-grossman-chairman-of-the-board-michael-demane-as-lead-director-300853473.html

SOURCE Nevro Corp.